Short answer
Prime Medicine, Inc. (PRME) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Prime Medicine’s Q3 2026 results and business highlights cover the quarter ended September 30, 2026.
Prime Medicine, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Prime Medicine’s Q3 2026 results and business highlights cover the quarter ended September 30, 2026
- Investors should review Exhibit 99.1 for the financial figures, operating performance and updated business developments
Item EX-99.1 · Exhibit EX-99.1
- First patient dosed in PM577a Phase 1/2 Wilson disease trial, marking Prime Medicine’s first in vivo clinical program
- FDA cleared PM647’s IND for Alpha-1 Antitrypsin Deficiency, with initial clinical data from PM577a and PM647 expected in 2027
- PM359 BLA submission planned for first half of 2027, creating a near-term regulatory catalyst for the ex vivo program
- November offering generated $134.7 million in net proceeds, extending funding runway through 2027
- Third-quarter net loss narrowed to $39.0 million from $50.6 million, while revenue rose to $4.2 million from $1.2 million
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Prime Medicine, Inc. 8-K filings
Get the next PRME 8-K as it lands
Follow PRME for push alerts, or ask the research agent what this filing means.